Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs BridgeBio Pharma Inc (BBIO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs BridgeBio Pharma Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $299.53 (market cap $39.89B), while BridgeBio Pharma Inc trades at $85.01 (market cap $16.81B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 2.4× BridgeBio Pharma Inc's market cap, and BridgeBio Pharma Inc is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | BBIO | |
|---|---|---|
Market Cap | $39.89B | $16.81B |
Sector | Health | Health |
52-Week High | $491.22 | $90.17 |
52-Week Low | $278.09 | $44.81 |
Enterprise Value | $38.15B | $18.36B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
BridgeBio Pharma (BBIO) trades at $85.89, down 4.75% today but remains near 52-week highs following positive clinical news. The stock shows strong technical momentum with bullish moving averages and support at $85. Fundamentally, revenue grew to $502M in 2025 but net losses widened to -$725M with negative cash flow from operations. Recent news highlights competitor setbacks boosting confidence in Attruby and a $1B preferred equity raise to fund launches.
Outlook hinges on successful drug launches and pipeline execution, with analyst consensus bullish (92% buy ratings) and a $103 price target. Key risks include sustained cash burn, clinical trial outcomes, and high valuation (P/S 28.5) pricing in future success. The stock offers growth potential but requires monitoring of profitability milestones.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →
